Moving averages are one of the core indicators in technical analysis. A Simple Moving Average (SMA) is simply the arithmetic average of stock price over a period. It is calculated by adding a selected range of prices, usually closing prices, and then dividing that figure by the number of time periods in that range.
The 50-Day SMA calculates the average price over 50 days. And the 20-Day SMA and 200-Day SMA calculates the average price over 20 days and 200 days separately.
As of today (2026-07-03), Santhera Pharmaceuticals Holding AG's 50-Day SMA is CHF16.38. It's 20-Day SMA is CHF15.78 and 200-Day SMA is CHF14.04.
Santhera Pharmaceuticals Holding AG (XSWX:SANN) 50-Day SMA Explanation
Simple Moving Average (SMA) is the arithmetic average of stock price over a period. The 20-Day SMA calculates the average price over 20 days. And the 50-Day SMA and 200-Day SMA calculates the average price over 50 days and 200 days separately. SMAs are often used to determine the price trend direction. A 200-Day SMA is usually a proxy for the long-term trend, while shorter periods indicate short-term trend.
SMA are commonly compared with stock price or different period SMAs to indicate a trading signal. Generally speaking, if the price goes above the SMA, or a short-term SMA crosses above a long-term SMA, an uptrend is expected, investors may want to go long or cover short. Conversely, if the price goes below the SMA, or the short-term SMA crosses below a long-term SMA, a downtrend is expected, investors may want to go short or exit long.
Two popular trading patterns that use SMA include the death cross and a golden cross. A death cross occurs when the 50-day SMA crosses below the 200-day SMA. This is considered a bearish signal, that further losses are in store. The golden cross is a bullish signal which occurs when a short-term SMA crosses above a long-term SMA.
Santhera Pharmaceuticals Holding AG 50-Day SMA Related Terms
XSWX:SANN vs VRTX, REGN, ALNY: 50-Day SMA Comparison
For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's 50-Day SMA, along with its competitors' market caps and 50-Day SMA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santhera Pharmaceuticals Holding AG 50-Day SMA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's 50-Day SMA distribution charts can be found below:
* The bar in red indicates where Santhera Pharmaceuticals Holding AG's 50-Day SMA falls into.
Santhera Pharmaceuticals Holding AG (XSWX:SANN) 50-Day SMA Calculation
The formula for calculating SMA is:
SMA
=
( P1 + P2 + ... + Pn )
/
n
where:
Pn is the price of the stock at period n.
n is the total number of periods.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG (XSWX:SANN) has a 50-Day SMA of CHF16.38 as of Jul. 03, 2026. Simple Moving Average (SMA) is the arithmetic average of stock price over a period. View historical data on Santhera Pharmaceuticals Holding AG and its competitors.
Is Santhera Pharmaceuticals Holding AG's 50-Day SMA too high?
Santhera Pharmaceuticals Holding AG's current 50-Day SMA is CHF16.38. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's 50-Day SMA compare to VRTX and REGN?
Santhera Pharmaceuticals Holding AG's 50-Day SMA of CHF16.38 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 50-Day SMA for a Biotechnology company?
A good 50-Day SMA depends on the Biotechnology industry context. However, 50-Day SMA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 50-Day SMA mean?
A high 50-Day SMA can signal that a stock is expensive relative to its fundamentals. Simple Moving Average (SMA) is the arithmetic average of stock price over a period. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. Santhera Pharmaceuticals Holding AG's current 50-Day SMA is CHF16.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG (XSWX:SANN) is currently considered Possible Value Trap. The stock's GF Value™ is CHF23.24, compared to a current price of CHF15.20 — trading 34.6% below its estimated fair value. The current 50-Day SMA is CHF16.38. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 50-Day SMA calculated?
50-Day SMA is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (XSWX:SANN), the current 50-Day SMA is CHF16.38 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santhera Pharmaceuticals Holding AG (XSWX:SANN) Overvalued in 2026?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued.
The current stock price of CHF15.20 is trading 34.6% below its estimated GF Value™ of CHF23.24.
GuruFocus considers Santhera Pharmaceuticals Holding AG to be Possible Value Trap.
Key valuation signals for XSWX:SANN:
50-Day SMA: CHF16.38
GF Value™: CHF23.24 vs. price of CHF15.20 (34.6% below fair value)
No single metric tells the full story. See the XSWX:SANN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santhera Pharmaceuticals Holding AG Business Description
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
39GF Score
Get the complete analysis for XSWX:SANN
50-Day SMA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SANN has been successfully added to your 